OrthoPediatrics (NASDAQ:KIDS – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.
Profitability
This table compares OrthoPediatrics and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OrthoPediatrics | -16.31% | -7.01% | -4.86% |
| Sight Sciences | -46.83% | -52.34% | -28.49% |
Valuation and Earnings
This table compares OrthoPediatrics and Sight Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OrthoPediatrics | $236.35 million | 2.05 | -$39.65 million | ($1.68) | -11.21 |
| Sight Sciences | $79.55 million | 3.61 | -$38.43 million | ($0.71) | -7.44 |
Sight Sciences has lower revenue, but higher earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
OrthoPediatrics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500.
Insider & Institutional Ownership
69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 32.7% of OrthoPediatrics shares are owned by insiders. Comparatively, 30.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and price targets for OrthoPediatrics and Sight Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OrthoPediatrics | 1 | 1 | 9 | 0 | 2.73 |
| Sight Sciences | 1 | 3 | 5 | 0 | 2.44 |
OrthoPediatrics presently has a consensus target price of $24.44, suggesting a potential upside of 29.81%. Sight Sciences has a consensus target price of $8.14, suggesting a potential upside of 54.09%. Given Sight Sciences’ higher probable upside, analysts clearly believe Sight Sciences is more favorable than OrthoPediatrics.
Summary
OrthoPediatrics beats Sight Sciences on 8 of the 14 factors compared between the two stocks.
About OrthoPediatrics
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
